Study of Vel-101 to prevent kidney transplant rejection
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new medicine called VEL-101, which is added to standard anti-rejection drugs, to see if it helps prevent the body from rejecting a new kidney. It is for adults receiving a kidney from a deceased or non-identical living donor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are getting a kidney from a deceased donor or a living donor who is not an identical twin
- You have not had a previous kidney transplant that failed due to rejection or disease within the first year
- You do not have certain infections like hepatitis B, C, or HIV
- You do not have a history of cancer in the last 5 years (except minor skin cancer that was treated)
- You are willing to use effective birth control for 3 months after the study ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses DNA testing and gene expression profiling to see if kidney transplant recipients can safely switch to a belatacept-only immunosuppression regimen. The goal is to simplify your anti-rejection drugs while keeping your kidney healthy.
This study tests a new medicine called TNX-1500 that may help prevent the body from rejecting a new kidney. It is for people who are already waiting for a kidney transplant and aims to make the transplant more successful.
This study looks at whether Envarsus XR helps prevent “subclinical” (not obviously noticeable) kidney transplant rejection by changing blood immune test results. You may be able to join if you recently received a kidney transplant and can take the study medicine as required.
This study looks at how well a once-daily anti-rejection medicine (Envarsus) works in people who have just had a kidney transplant. It helps doctors understand the best way to use this medicine and manage side effects.
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
This Phase 1/2 trial tests how safe AT 1501 is and how it works in people getting their first kidney transplant. It aims to improve transplant outcomes by targeting the immune system, while carefully watching for side effects and immune compatibility issues.
Hear when a new Transplantation, Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.